Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly
AMGN [NASD]
Amgen Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E17.87 EPS (ttm)5.91 Insider Own0.13% Shs Outstand749.98M Perf Week-0.58%
Market Cap79.22B Forward P/E12.79 EPS next Y8.26 Insider Trans15.39% Shs Float749.41M Perf Month-1.27%
Income4.60B PEG1.90 EPS next Q1.74 Inst Own83.18% Short Float1.31% Perf Quarter26.90%
Sales17.46B P/S4.54 EPS this Y36.71% Inst Trans-0.52% Short Ratio2.24 Perf Half Y26.96%
Book/sh26.00 P/B4.06 EPS next Y13.46% ROA9.11% Target Price112.95 Perf Year52.23%
Cash/sh28.36 P/C3.72 EPS next 5Y9.39% ROE23.95% 52W Range66.37 - 114.44 Perf YTD23.75%
Dividend1.88 P/FCF19.46 EPS past 5Y15.03% ROI10.51% 52W High-7.70% Beta0.41
Dividend %1.78% Quick Ratio5.05 Sales past 5Y3.17% Gross Margin82.97% 52W Low59.15% ATR2.76
Employees18000 Current Ratio5.58 Sales Q/Q4.69% Oper. Margin31.75% RSI (14)52.23 Volatility2.44% 2.43%
OptionableYes Debt/Eq1.23 EPS Q/Q21.11% Profit Margin26.32% Rel Volume0.70 Prev Close104.97
ShortableYes LT Debt/Eq1.23 EarningsApr 23 AMC Payout25.64% Avg Volume4.37M Price105.63
Recom2.40 SMA20-0.90% SMA503.03% SMA20018.33% Volume3,037,833 Change0.63%
24-Apr-13Reiterated Deutsche Bank Buy $108 → $115
15-Apr-13Reiterated Barclays Equal Weight $90 → $105
08-Apr-13Reiterated RBC Capital Mkts Outperform $95 → $105
25-Jan-13Upgrade Argus Hold → Buy $96
24-Jan-13Reiterated UBS Buy $96 → $98
12-Sep-12Downgrade Robert W. Baird Outperform → Neutral $84
10-Sep-12Upgrade UBS Neutral → Buy $80 → $96
02-Aug-12Downgrade Argus Buy → Hold
15-Mar-12Resumed Stifel Nicolaus Hold
09-Feb-12Downgrade Oppenheimer Outperform → Perform
09-Sep-11Downgrade Standpoint Research Buy → Hold
10-May-11Reiterated MP Advisors Outperform $63 → $65
25-Apr-11Reiterated Stifel Nicolaus Buy $70 → $68
21-Apr-11Reiterated Oppenheimer Outperform $66 → $63
14-Mar-11Initiated Standpoint Research Buy $66
25-Jan-11Reiterated Barclays Capital Overweight $76 → $72
14-Dec-10Reiterated UBS Neutral $56 → $58
14-Dec-10Reiterated Stifel Nicolaus Buy $70 → $75
14-Dec-10Reiterated Barclays Capital Overweight $71 → $76
22-Nov-10Downgrade MP Advisors Outperform → Market Perform $65 → $63
19-May-13 09:14AM  China Biotech In Review: SciClone Pharma In-Licenses China Rights To Heart Failure Drug at Seeking Alpha
18-May-13 01:03AM  Here's Why Amgen Shares Are Worth $117 To $126 Today at Seeking Alpha
17-May-13 06:03PM  Final Glance: Biotechnology companies AP
01:32PM  Midday Glance: Biotechnology companies AP
10:25AM  Early Glance: Biotechnology companies AP
16-May-13 06:03PM  Final Glance: Biotechnology companies AP
04:18PM  Amgen To Present At The UBS Global Life Sciences Conference PR Newswire
03:35PM  Eyeing Business Models and Practices that are Sustainable and Value-Creating in the Biotech and Pharmaceutical Sectors Wall Street Transcript
03:29PM  Gilead Drug For Leukemia Shows Success In Early Trial at Investor's Business Daily
01:29PM  Midday Glance: Biotechnology companies AP
01:04PM  AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward at TheStreet
12:40PM  Tennis With Evert, Baseball With Microsoft: D.C. Scene at Bloomberg
10:35AM  Early Glance: Biotechnology companies AP
10:04AM  Best And Worst ETFs, Mutual Funds And Key Holdings: All-Cap Value Style at Seeking Alpha
08:28AM  Sanofi and Regeneron's Latest Partnership at Motley Fool
07:51AM  The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals Zacks
15-May-13 06:02PM  Final Glance: Biotechnology companies AP
06:02PM  New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer PR Newswire
06:00PM  Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting PR Newswire
05:00PM  Sanofi/REGN Commence Enrollment Zacks
01:26PM  Midday Glance: Biotechnology companies AP
10:24AM  Early Glance: Biotechnology companies AP
10:14AM  [video] Health Overhaul May Ease Costs Study Finds at MarketWatch
08:00AM  Manatt, Jones Day, Howrey, Ropes & Gray: Business of Law at Bloomberg
14-May-13 07:04PM  [video] Obamacare May Ease Costs for Employers and Employees at MarketWatch
06:02PM  Final Glance: Biotechnology companies AP
05:00PM  Amgen Inc (AMGN): Today's Featured Drugs Winner at TheStreet
04:20PM  Amgen to Set Up JV in China Zacks
03:28PM  Don't Get Too Excited About This Cancer Drug Yet at Motley Fool
02:10PM  Midday Glance: Biotechnology companies AP
12:50PM  Celgene: Apremilast For Psoriatic Arthritis Offers Upside at Seeking Alpha
10:36AM  Early Glance: Biotechnology companies AP
13-May-13 06:02PM  Final Glance: Biotechnology companies AP
05:03PM  Monsanto Wins Seed Case as High Court Backs Patent Rights at Bloomberg
03:55PM  Big Pharma's Biggest Winners at Motley Fool
01:18PM  Midday Glance: Biotechnology companies AP
11:24AM  Is Regeneron A Value Pick In The Pharma Sector? at Seeking Alpha
10:23AM  Early Glance: Biotechnology companies AP
09:54AM  Amgen Stock To Go Ex-dividend Tomorrow (AMGN) at TheStreet
12-May-13 06:21PM  Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company? at Seeking Alpha
06:06PM  Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company? at Seeking Alpha
10:19AM  Letting Statistics Help You See What You Want To See at Seeking Alpha
03:54AM  China Biotech In Review: Sagent Buys Out China JV Partner For $25 Million at Seeking Alpha
10-May-13 06:02PM  Final Glance: Biotechnology companies AP
02:42PM  This $28 Billion Hedge Fund Is Bullish at Motley Fool
01:20PM  Midday Glance: Biotechnology companies AP
01:04PM  AMGEN INC Financials EDGAR Online Financials
12:25PM  Amgen Signs Chinese Partner for Vectibix at Motley Fool
10:34AM  Ex-Div Reminder for Amgen at Forbes
10:31AM  Early Glance: Biotechnology companies AP
09:10AM  Q1 Revenue In-Line. Amgen Deal Is Encouraging Zacks
07:45AM  TBIO: Q1 Revenue In-Line. Amgen Deal Is Encouraging Zacks Small Cap Research
09-May-13 06:03PM  Final Glance: Biotechnology companies AP
04:48PM  Amgen, Zhejiang Beta Pharma announce joint venture in China theflyonthewall.com
04:09PM  InPlay: Amgen and Zhejiang Beta Pharma announce planned joint venture in China Briefing.com
04:08PM  Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China PR Newswire
03:14PM  Why NPS Pharmaceuticals Is Up After Earnings at Motley Fool
01:21PM  Midday Glance: Biotechnology companies AP
10:40AM  Early Glance: Biotechnology companies AP
09:10AM  The Secret Stock Picks Of This Multi Billion Quant Hedge Fund at Seeking Alpha
03:46AM  Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector at Seeking Alpha
08-May-13 06:02PM  Final Glance: Biotechnology companies AP
01:28PM  Midday Glance: Biotechnology companies AP
11:30AM  Amgen Chased By The Bubble at Investopedia
10:36AM  Early Glance: Biotechnology companies AP
07-May-13 07:40PM  3 Hallmarks of a Megablockbuster at Motley Fool
06:02PM  Final Glance: Biotechnology companies AP
05:59PM  [video] U.S. Companies That Owe Employees a Raise at MarketWatch
04:08PM  InPlay: Amgen announces top-line results of Vectibix (panitumumab) Phase 3 head-to-head study against Erbitux (cetuximab) in metastatic colorectal cancer; the relative adverse event profiles were as anticipated for each of the anti-EGFR the Briefing.com
04:04PM  Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer PR Newswire
03:01PM  Midday Glance: Biotechnology companies AP
10:59AM  Fast climbing biotech Regeneron still has room to grow at Reuters
10:31AM  Early Glance: Biotechnology companies AP
09:07AM  X Factor: 5 Stocks Reaching Their Ex-Dividend Date on May 14 at Minyanville
06:53AM  Tackling the Rotation Dilemma TheStreet
06-May-13 06:30PM  Leading Biotechs Act Well But Be Careful Not To Chase at Investor's Business Daily
06:02PM  Final Glance: Biotechnology companies AP
05:01PM  Amgen Inc (AMGN): Today's Featured Health Care Laggard at TheStreet
04:45PM  After AbbVie's Humira: What Next? at Seeking Alpha
01:27PM  Midday Glance: Biotechnology companies AP
01:04PM  5 Stocks Dragging In The Health Care Sector at TheStreet
10:35AM  Early Glance: Biotechnology companies AP
04-May-13 06:00AM  All the Reasons in the World to Pull Back at TheStreet
03-May-13 06:05PM  Final Glance: Biotechnology companies AP
01:17PM  Midday Glance: Biotechnology companies AP
12:15PM  Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial at Seeking Alpha
12:12PM  Early Glance: Biotechnology companies AP
11:16AM  Wall Street Transcript Interview with Dr. Jason Kantor, Research Analyst at Credit Suisse Group: High Success Rates and Significant M&A in the Antibody Space Wall Street Transcript
09:30AM  This May Be The Best Pharmaceutical Stock for Income Investors The StreetAuthority Network
09:30AM  This May Be The Best Pharmaceutical Stock for Income Investors StreetAuthority Network
09:30AM  This May Be The Best Pharmaceutical Stock for Income Investors
09:24AM  AMGEN INC Files SEC form 10-Q, Quarterly Report EDGAR Online
06:03AM  Big drugmakers think small with nanomedicine deals at Reuters
01-May-13 06:08PM  Final Glance: Biotechnology companies AP
04:51PM  On the Call: Merck R&D director Roger Perlmutter AP
04:16PM  Drugs from Amgen, others assessed by FDA as radiation treatments at Reuters
04:05PM  Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California PR Newswire
02:37PM  DreamWorks Gets a Thumbs Up and 4 More Analyst Upgrades To Know at Wall St. Cheat Sheet
01:17PM  Midday Glance: Biotechnology companies AP
12:30PM  Earnings Beat at Hospira Zacks
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patton Cynthia MSVP & CCOMay 16Option Exercise54.583,544193,43718,986May 17 05:42 PM
Patton Cynthia MSVP & CCOMay 16Sale105.013,544372,14815,442May 17 05:42 PM
BIONDI FRANKDirectorMay 14Option Exercise56.5010,000564,95039,780May 16 05:38 PM
PELHAM JUDITH CDirectorMay 14Option Exercise55.4725,0001,386,65048,149May 16 05:42 PM
BIONDI FRANKDirectorMay 14Sale108.4310,0001,084,31829,780May 16 05:38 PM
PELHAM JUDITH CDirectorMay 14Sale108.2525,0002,706,16523,149May 16 05:42 PM
de Carbonnel FrancoisDirectorApr 30Option Exercise54.7410,000547,40021,930May 02 06:26 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 29Option Exercise50.4410,000504,40064,643Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 29Sale107.0210,0001,070,19154,643Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 26Option Exercise58.4310,000584,30066,077Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 26Sale107.9910,0001,079,87256,077Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 25Option Exercise54.698,662473,72565,973Apr 26 05:33 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 25Sale107.958,662935,02957,311Apr 26 05:33 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 24Sale105.956,924733,56558,311Apr 26 05:33 PM
de Carbonnel FrancoisDirectorMar 13Option Exercise54.7410,000547,40017,805Mar 14 06:18 PM
BALTIMORE DAVIDDirectorFeb 28Option Exercise74.895,000374,45035,526Mar 01 05:31 PM
BALTIMORE DAVIDDirectorFeb 28Sale92.9488682,34530,526Mar 01 05:31 PM
HERRINGER FRANK CDirectorFeb 26Option Exercise74.895,000374,45021,262Feb 26 06:20 PM
PELHAM JUDITH CDirectorFeb 08Option Exercise62.555,000312,75026,304Feb 11 07:56 PM
PELHAM JUDITH CDirectorFeb 08Sale86.945,000434,71521,304Feb 11 07:56 PM
Bradway Robert APresident and CEODec 20Option Exercise64.5640,0002,582,400141,711Dec 20 06:34 PM
BALTIMORE DAVIDDirectorDec 10Option Exercise50.7816,000812,48046,526Dec 12 06:40 PM
BALTIMORE DAVIDDirectorDec 10Sale89.006,800605,22030,526Dec 12 06:40 PM
SCHAEFFER LEONARD DDirectorDec 07Option Exercise51.7115,000775,60031,329Dec 10 07:09 PM
SCHAEFFER LEONARD DDirectorDec 07Sale87.9215,0001,318,83016,329Dec 10 07:09 PM
BIONDI FRANKDirectorNov 29Option Exercise74.895,000374,45032,833Nov 29 06:50 PM
BIONDI FRANKDirectorNov 29Sale88.105,000440,51227,833Nov 29 06:50 PM
OMENN GILBERT SDirectorNov 26Option Exercise57.6826,0001,499,680202,783Nov 26 08:45 PM
OMENN GILBERT SDirectorNov 26Sale87.1126,0002,264,985176,783Nov 26 08:45 PM
SHARER KEVIN WDirectorOct 24Option Exercise71.88195,00014,016,600296,018Oct 25 06:32 PM
SHARER KEVIN WDirectorOct 24Sale88.13263,00023,178,5985,494Oct 25 06:32 PM
SHARER KEVIN WDirectorSep 11Option Exercise61.36274,62516,849,739375,643Sep 12 05:24 PM
SHARER KEVIN WDirectorSep 11Sale83.96349,62529,355,36573,494Sep 12 05:24 PM
SCHAEFFER LEONARD DDirectorAug 30Option Exercise74.895,000374,45021,316Aug 31 06:00 PM
SCHAEFFER LEONARD DDirectorAug 30Sale83.255,000416,25416,316Aug 31 06:00 PM
PELHAM JUDITH CDirectorAug 24Option Exercise74.895,000374,45026,304Aug 27 06:53 PM
PELHAM JUDITH CDirectorAug 24Sale84.375,000421,83321,304Aug 27 06:53 PM
REASON J PAULDirectorAug 09Sale81.934,500368,69223,591Aug 13 06:56 PM
REASON J PAULDirectorAug 06Option Exercise53.6525,0001,341,20044,408Aug 08 06:14 PM
RICHO ANNASVP & CCOAug 01Option Exercise62.635,125320,97941,992Aug 01 07:50 PM
RICHO ANNASVP & CCOAug 01Sale83.065,125425,69810,256Aug 01 07:50 PM
Dittrich Thomas J.W.VP, Finance & CAOJul 31Option Exercise65.2832,1502,098,64545,871Aug 01 07:39 PM
Dittrich Thomas J.W.VP, Finance & CAOJul 31Sale82.6932,1502,658,38713,721Aug 01 07:39 PM
SCOTT DAVID JSVP, Gen. Counsel & Secy.Jul 30Option Exercise58.60113,5006,651,180179,058Jul 31 08:00 PM
REASON J PAULDirectorJul 30Option Exercise73.2710,000732,65028,139Jul 31 07:21 PM
BONANNI FABRIZIOEVP, OperationsJul 30Sale84.3312,1371,023,56248,491Jul 31 07:31 PM
SCOTT DAVID JSVP, Gen. Counsel & Secy.Jul 30Sale84.11113,5009,546,57865,558Jul 31 08:00 PM
BIONDI FRANKDirectorJul 27Option Exercise48.7221,0001,023,13048,785Jul 31 07:14 PM
BONANNI FABRIZIOEVP, OperationsJul 27Option Exercise54.53303,01116,522,165376,510Jul 31 07:31 PM
Harper Sean EEVP, Research & DevelopmentJul 27Option Exercise68.4339,9002,730,17284,332Jul 31 07:35 PM
SHARER KEVIN WDirectorJul 27Option Exercise46.29128,0005,924,480228,979Jul 31 07:26 PM
MCNAMEE BRIAN MSVP, Human ResourcesJul 27Option Exercise62.5385,0985,321,035138,387Jul 31 07:46 PM
RICHO ANNASVP & CCOJul 27Option Exercise71.887,875566,05544,742Jul 31 07:52 PM
RICHO ANNASVP & CCOJul 27Sale81.817,875644,23010,256Jul 31 07:52 PM
MCNAMEE BRIAN MSVP, Human ResourcesJul 27Sale82.7385,5987,081,85952,789Jul 31 07:46 PM
Harper Sean EEVP, Research & DevelopmentJul 27Sale82.3339,9003,285,08752,432Jul 31 07:35 PM
BONANNI FABRIZIOEVP, OperationsJul 27Sale82.14303,01124,888,71860,628Jul 31 07:31 PM
SHARER KEVIN WDirectorJul 27Sale82.68128,00010,583,347148,494Jul 31 07:26 PM
BIONDI FRANKDirectorJul 27Sale82.3021,0001,728,30027,785Jul 31 07:14 PM
SCOTT DAVID JSVP, Gen. Counsel & Secy.Jul 27Sale82.0030,0002,460,00065,558Jul 31 08:00 PM
open in yahoo | open in reuters | open in google